{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:11:07Z","timestamp":1744884667607},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Behandlung mittels Androgendeprivationstherapie (ADT) plus erweiterter Hormontherapie (ARTA) stellt die Standardtherapie beim metastasierten hormonsensiblen Prostatakarzinom (mHSPC) dar. Neue Daten von Triplet-Kombinationstherapien aus ADT\u202f+\u2009ARTA (Abirateron\/Darolutamid)\u202f+\u2009Docetaxel-Chemotherapie zeigten einen \u00dcberlebensvorteil f\u00fcr gewisse mHSPC-Patientengruppen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Welches Therapieansprechen ist im Real-world-mHSPC-Setting mittels Triplet-Kombinationstherapie zu erwarten und welche Nebenwirkungen treten geh\u00e4uft auf?<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Alle Patienten, die eine Triplet-Kombinationstherapie aus ADT\u202f+\u2009ARTA (Abirateron\/Darolutamid)\u202f+\u2009Docetaxel erhalten haben, wurden f\u00fcr die vorliegende Studie eingeschlossen. Insgesamt konnten 14\u00a0Patienten mit einem medianen Alter von 62\u00a0Jahren und 10\/14 Abirateron- bzw. 4\/14 Darolutamid-Therapien inkludiert werden. Der mediane PSA vor Therapiebeginn lag bei 77\u202f(IQR 44\u2013150) ng\/ml. Insgesamt hatten 86\u202f% der Patienten einen PSA-Abfall &gt;\u202f90\u202f% unter Therapie und der mediane PSA-Nadir lag bei 0,3\u202fng\/ml. Schwerwiegende Nebenwirkungen (Grad\u00a0III) unter der Triplet-Therapie traten bei insgesamt 2\u00a0Patienten (14,2\u202f%) auf mit fieberhafter Neutropenie 7,1\u202f% (1\/14) bzw. Gastroenteritis und Infektgeschehen 7,1\u202f% (1\/14). Leichtgradige Nebenwirkungen (Grad\u00a0I\/II) wie Polyneuropathie (1\/14), Mukositis (1\/14), Xerostomie (1\/14), Gewichtsverlust (1\/14) und Fatigue (3\/14) wurden ebenso detektiert. Die Chemotherapie wurde bei einem Patienten aufgrund von Nebenwirkungen unterbrochen. Nach einem medianen Follow-up von 10 (IQR: 7\u201317) Monaten zeigten sich 2\u00a0Patienten (14,2\u202f%) mit Progression zu einer Kastrationsresistenz.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Zusammenfassung<\/jats:title>\n                <jats:p>Die Triplet-Therapie zeigt sich im klinischen Alltag mit einem sehr guten PSA-Ansprechen. Nebenwirkungen unter der Therapie sind v.\u202fa. durch die klassische Chemotherapie getriggert.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00120-023-02253-8","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:02:10Z","timestamp":1703174530000},"page":"254-261","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Erste klinische und onkologische Erfahrungen mit der Triplet-Therapie beim \u201ehigh-volume\u201c metastasierten hormonsensiblen Prostatakarzinom","First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kasparek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"von Koskull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Banek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"2253_CR1","volume-title":"EAU guidelines on prostate cancer","author":"N Mottet","year":"2019","unstructured":"Mottet\u00a0N, van den Bergh\u00a0RCN, Briers\u00a0E, Bourke\u00a0L, Cornford\u00a0P, De Santis\u00a0M, Gillessen\u00a0S, Govorov\u00a0A, Grummet\u00a0J, Henry\u00a0AM, Lam\u00a0TB, Mason\u00a0MD, van der Poel\u00a0HG, van der Kwast\u00a0TH, Rouvi\u00e8re\u00a0O (2019) EAU guidelines on prostate cancer. Wiegel (Published online)"},{"key":"2253_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2020.12.003","author":"F Preisser","year":"2021","unstructured":"Preisser\u00a0F, Chun Felix\u00a0KH, Banek\u00a0S et\u00a0al (2021) Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int. https:\/\/doi.org\/10.1016\/j.prnil.2020.12.003","journal-title":"Prostate Int"},{"key":"2253_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.08.007","author":"P Mandel","year":"2022","unstructured":"Mandel\u00a0P, Hoeh\u00a0B, Wenzel\u00a0M et\u00a0al (2022) Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a\u00a0systematic review and network meta-analysis. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2022.08.007 (S2405\u20134569(22)00176-6)","journal-title":"Eur Urol Focus"},{"key":"2253_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.03.024","author":"B Hoeh","year":"2023","unstructured":"Hoeh\u00a0B, Garcia\u00a0CC, Wenzel\u00a0M et\u00a0al (2023) Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2023.03.024 (S2405\u20134569(23)00094-9)","journal-title":"Eur Urol Focus"},{"issue":"4","key":"2253_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00120-023-02029-0","volume":"62","author":"M Wenzel","year":"2023","unstructured":"Wenzel\u00a0M, Hoeh\u00a0B, Chun\u00a0FKH, Mandel\u00a0P (2023) Androgen deprivation therapy plus chemotherapy\u00a0\u00b1 androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer. Urologie 62(4):360\u2013368. https:\/\/doi.org\/10.1007\/s00120-023-02029-0","journal-title":"Urologie"},{"issue":"11","key":"2253_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos\u00a0CE, Chen\u00a0YH, Carducci\u00a0MA et\u00a0al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase\u00a0III E3805 CHAARTED trial. j Clin Oncol 36(11):1080\u20131087. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657","journal-title":"j Clin Oncol"},{"issue":"4","key":"2253_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi\u00a0K, Tran\u00a0N, Fein\u00a0L et\u00a0al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. n Engl J Med 377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"n Engl J Med"},{"key":"2253_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.04.003","author":"M Wenzel","year":"2021","unstructured":"Wenzel\u00a0M, W\u00fcrnschimmel\u00a0C, Nocera\u00a0L et\u00a0al (2021) Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2021.04.003 (S2405\u20134569(21)00109-7)","journal-title":"Eur Urol Focus"},{"issue":"12","key":"2253_CR9","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke\u00a0NW, Ali\u00a0A, Ingleby\u00a0FC et\u00a0al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992\u20132003. https:\/\/doi.org\/10.1093\/annonc\/mdz396","journal-title":"Ann Oncol"},{"issue":"4","key":"2253_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James\u00a0ND, de Bono\u00a0JS, Spears\u00a0MR et\u00a0al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N\u00a0Engl J Med 377(4):338\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1702900","journal-title":"N Engl J Med"},{"issue":"2","key":"2253_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis\u00a0ID, Martin\u00a0AJ, Stockler\u00a0MR et\u00a0al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. n Engl J Med 381(2):121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","journal-title":"n Engl J Med"},{"issue":"32","key":"2253_CR12","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong\u00a0AJ, Szmulewitz\u00a0RZ, Petrylak\u00a0DP et\u00a0al (2019) ARCHES: a\u00a0randomized, phase\u00a0III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. j Clin Oncol 37(32):2974\u20132986. https:\/\/doi.org\/10.1200\/JCO.19.00799","journal-title":"j Clin Oncol"},{"issue":"1","key":"2253_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi\u00a0KN, Agarwal\u00a0N, Bjartell\u00a0A et\u00a0al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"issue":"12","key":"2253_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith\u00a0MR, Hussain\u00a0M, Saad\u00a0F et\u00a0al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. n Engl J Med 386(12):1132\u20131142. https:\/\/doi.org\/10.1056\/NEJMoa2119115","journal-title":"n Engl J Med"},{"issue":"10336","key":"2253_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi\u00a0K, Foulon\u00a0S, Carles\u00a0J et\u00a0al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0study with a\u00a02\u00a0\u00d7 2 factorial design. Lancet 399(10336):1695\u20131707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"2253_CR16","doi-asserted-by":"publisher","first-page":"659135","DOI":"10.3389\/fonc.2021.659135","volume":"11","author":"M Wenzel","year":"2021","unstructured":"Wenzel\u00a0M, Preisser\u00a0F, Hoeh\u00a0B et\u00a0al (2021) Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies. Front Oncol 11:659135. https:\/\/doi.org\/10.3389\/fonc.2021.659135","journal-title":"Front Oncol"},{"key":"2253_CR17","unstructured":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase\u00a0III ARASENS trial\u2014pubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/36795843\/. Zugegriffen: 28. Juli 2023"},{"issue":"4","key":"2253_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara\u00a0N, Chi\u00a0KN, \u00d6zg\u00fcro\u011flu\u00a0M et\u00a0al (2020) Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with Abiraterone acetate plus Prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase\u00a03 LATITUDE study. Eur Urol 77(4):494\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021","journal-title":"Eur Urol"},{"issue":"24","key":"2253_CR19","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain\u00a0M, Tangen\u00a0CM, Higano\u00a0C et\u00a0al (2006) Absolute prostate-specific antigen value after androgen deprivation is a\u00a0strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162). j Clin Oncol 24(24):3984\u20133990. https:\/\/doi.org\/10.1200\/JCO.2006.06.4246","journal-title":"j Clin Oncol"},{"key":"2253_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00696-w","author":"G Gebrael","year":"2023","unstructured":"Gebrael\u00a0G, Sayegh\u00a0N, Thomas\u00a0VM et\u00a0al (2023) Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00696-w","journal-title":"prostate Cancer Prostatic Dis"},{"key":"2253_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04189-8","author":"M Kafka","year":"2022","unstructured":"Kafka\u00a0M, Burtscher\u00a0T, Fritz\u00a0J et\u00a0al (2022) Real-world comparison of docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir \u2264\u202f0.05\u202fng\/ml as marker for treatment response. World J Urol. https:\/\/doi.org\/10.1007\/s00345-022-04189-8","journal-title":"World J Urol"},{"issue":"5","key":"2253_CR22","doi-asserted-by":"publisher","first-page":"252.e19","DOI":"10.1016\/j.urolonc.2023.03.013","volume":"41","author":"B Lowentritt","year":"2023","unstructured":"Lowentritt\u00a0B, Pilon\u00a0D, Waters\u00a0D et\u00a0al (2023) Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: a\u00a0retrospective cohort study. Urol Oncol 41(5):252.e19\u2013252.e27. https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.013","journal-title":"Urol Oncol"},{"issue":"5","key":"2253_CR23","doi-asserted-by":"publisher","first-page":"253.e1","DOI":"10.1016\/j.urolonc.2023.03.003","volume":"41","author":"B Lowentritt","year":"2023","unstructured":"Lowentritt\u00a0B, Pilon\u00a0D, Khilfeh\u00a0I et\u00a0al (2023) Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: a\u00a0comparison of patients initiated on apalutamide or enzalutamide. Urol Oncol 41(5):253.e1\u2013253.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.003","journal-title":"Urol Oncol"},{"key":"2253_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00395-4","author":"M Wenzel","year":"2021","unstructured":"Wenzel\u00a0M, Nocera\u00a0L, Coll\u00e0 Ruvolo\u00a0C et\u00a0al (2021) Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a\u00a0systematic review and network meta-analysis. prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-021-00395-4 (30)","journal-title":"prostate Cancer Prostatic Dis"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02253-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:03:55Z","timestamp":1709737435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02253-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02253-8","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"23 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Finanzielle\/Reisekostenaufwendungen erhalten die Autoren wie folgt: M.\u00a0Wenzel (Ipsen, Pfizer, Janssen), B.\u00a0Hoeh (Ipsen, Janssen), F.K.\u00a0H.\u00a0Chun (Astellas, AstraZeneca, Apogepha, Janssen, Boston Scientific, Novartis, Olympus, Ipsen, Bayer), S.\u00a0Banek (MSD, Merck, IPSEN, BMS, Janssen, Pfizer) und P.\u00a0Mandel (Amgen, Astellas, AstraZeneca, Bayer, Ipsen, Janssen, MSD, Orion, Sanofi, Novartis). J.\u00a0Kasparek, C.\u00a0Humke und S.\u00a0von Koskull geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}